Atara Biotherapeutics has been granted a patent for methods of treating solid malignant tumors using antigen-specific T cells. The patent includes steps for informing patients about potential risks, monitoring tumor flare, and managing adverse reactions during treatment. GlobalData’s report on Atara Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Atara Biotherapeutics, CAR-T cell-based compositions was a key innovation area identified from patents. Atara Biotherapeutics's grant share as of April 2024 was 7%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of solid malignant tumors using antigen-specific t cells
A recently granted patent (Publication Number: US11925663B2) outlines a method for treating solid malignant tumors in human patients using antigen-specific T cells. The method involves administering a population of human cells containing at least 70% T cells that are specific for antigens of the tumor, without genetic engineering. The patent details steps for managing tumor flare reactions, grading them based on severity, and providing appropriate medical interventions. The method is specifically designed for treating lymphomas, such as diffuse large B-cell lymphoma (DLBCL) and plasmablastic lymphoma (PBL), and includes monitoring patients for tumor flare indications and adjusting treatment accordingly.
Furthermore, the patent describes scenarios where patients develop tumor flare reactions of varying severity (Grade 2, 3, or 4) after cell administration. Depending on the grade of the tumor flare, different interventions are recommended, ranging from medical treatment with pain medications for Grade 2 flare to hospitalization and airway protection for Grade 4 flare. The method also includes provisions for stopping treatment if the tumor flare poses a life-threatening risk and resuming treatment once the flare subsides. The patent emphasizes the importance of monitoring patients for tumor flare reactions, especially in lymphomas positive for Epstein-Barr virus (EBV), and highlights the need for personalized interventions based on the specific tumor site and patient response.
To know more about GlobalData’s detailed insights on Atara Biotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
